NexImmune, Inc. (NEXI)

3.4200 +0.3000 (+9.62%) As of 02:03PM EDT. Market open.

NexImmune, Inc.

9119 Gaither Road
Gaithersburg, MD 20877
United States
301 825 9810
https://www.neximmune.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 6

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Kristi Jones R.Ph.	CEO, President & Director	989.28k	N/A	1963
Dr. Mathias Oelke Ph.D.	Chief Scientific Officer	605.78k	N/A	1968
Mr. John Trainer M.B.A.	Consultant	1.33M	N/A	1974
Mr. Albert Nicholas Marchio II	Interim CFO & Principal Accounting Officer	N/A	N/A	1952
Mr. Karen Haslbeck	Head of Human Resources	N/A	N/A	N/A
Dr. Daniel P. Bednarik	Senior Vice President of Molecular Engineering & Protein Design	N/A	N/A	N/A
Dr. Robert Douglas Knight M.D.	Chief Medical Officer	454.77k	N/A	1951
Mr. Chad Rubin	Senior Vice President of Corporate Affairs	N/A	N/A	N/A
Dr. Jack A. Ragheb M.D., Ph.D.	Senior Vice President of Translational Science	N/A	N/A	N/A
Mr. Matthew Schiller	Head of Business Development	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. The company was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

Corporate governance

NexImmune, Inc.’s ISS governance QualityScore as of 1 May 2024 is 10. The pillar scores are Audit: 9; Board: 8; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.